CYCLOPHOSPHAMIDE Powder for solution for injection/infusion (2017)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion.
Qualitative and quantitative composition
Each vial of Cyclophosphamide 1000 mg Powder for Solution for Injection or Infusion contains 1069.0 mg cyclophosphamide monohydrate equivalent to 1000 mg cyclophosphamide. Strength after reconstitution: ...
Pharmaceutical form
Powder for solution for injection/infusion. White crystalline powder.
Therapeutic indications
Cyclophosphamide may be used alone or in combination with other chemotherapeutic agents, depending on the indication. Cyclophosphamide is indicated in the treatment of: Chronic Lymphocytic Leukemia (CLL). ...
Posology and method of administration
Cyclophosphamide should only be used by clinicians experienced in the use of cancer chemotherapy. Cyclophosphamide should only be administered where there are facilities for regular monitoring of clinical, ...
Contraindications
Cyclophosphamide is contra-indicated in patients with: Hypersensitivity to cyclophosphamide, any of its metabolites. Cute infections. Bone marrow aplasia or bone marrow depression prior to treatment. ...
Special warnings and precautions for use
Warnings Anaphylactic Reactions, Cross-sensitivity with Other Alkylating Agents Anaphylactic reactions including those with fatal outcomes have been reported in association with cyclophosphamide. Possible ...
Interaction with other medicinal products and other forms of interaction
Cyclophosphamide is inactive, but is metabolised in the liver, mainly by CYP2A6, 2B6, 2C9, 2C19 and 3A4, into two active metabolites. Planned co-administration or sequential administration of other substances ...
Fertility, pregnancy and lactation
Women of childbearing potential Girls treated with cyclophosphamide during pre-pubescence generally develop secondary sexual characteristics normally and have regular menses. Girls treated with cyclophosphamide ...
Effects on ability to drive and use machines
Patients undergoing treatment with cyclophosphamide may experience undesirable effects (including nausea, vomiting, dizziness, blurred vision, visual impairment) which could affect the ability to drive ...
Undesirable effects
The frequency of adverse reactions reported in the table below are derived from clinical trials and from post marketing experience and are defined using the following convention: very common (≥1/10), common ...
Overdose
Serious consequences of overdosage include manifestations of dose dependent toxicities such as myelosuppression, urotoxicity, cardiotoxicity (including cardiac failure), veno occlusive hepatic disease, ...
Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic and Immunomodulating Agents; Antineoplastic agents. Alkylating agents. Nitrogen mustard analogues ATC code: L01AA01 Cyclophosphamide has been demonstrated to have ...
Pharmacokinetic properties
Cyclophosphamide is administered as an inactive prodrug that is activated in the liver. Absorption Cyclophosphamide is quickly and almost completely absorbed from parenteral sites. Distribution Less than ...
Preclinical safety data
Acute toxicity The acute toxicity of cyclophosphamide is relatively low. This was demonstrated in studies on mice, guinea pigs, rabbits and dogs. Chronic toxicity Chronic administration of toxic doses ...
List of excipients
None.
Incompatibilities
Not applicable.
Shelf life
Shelf life: 2 years. Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C-8°C for the reconstituted solution. From a microbiological point of view, the reconstituted solution ...
Special precautions for storage
Do not store above 25°C. For storage conditions after reconstitution of the medicinal product, see section 6.3.
Nature and contents of container
Cyclophosphamide, Powder for Solution for Injection or Infusion, is available in the following pack sizes: 1, 5 or 10 clear colourless 100 ml Type I-glass vials containing 1000 mg cyclophosphamide sealed ...
Special precautions for disposal and other handling
For each 100 mg of cyclophosphamide, 5 ml of solvent must be added for reconstitution. The choice of diluent for reconstituting Cyclophosphamide containing cyclophosphamide depends on the route of administration ...
Marketing authorization holder
Sandoz Limited, Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR, United Kingdom
Marketing authorization number(s)
PL 04416/1394
Date of first authorization / renewal of the authorization
Date of first authorisation: 18 August 2014
Date of revision of the text
07/06/2017
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: